» Articles » PMID: 38851646

Three-Month Excessive Body Weight Loss < 37.7% As a Predictor of Mid-term Suboptimal Outcomes Postlaparoscopic Sleeve Gastrectomy: Risk Factors and the Impact of Neutrophil-to-Lymphocyte Ratio on Adipocyte Function

Overview
Journal Obes Surg
Date 2024 Jun 8
PMID 38851646
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: This study aimed to evaluate the impact of achieving < 37.7% excess body-weight loss (EBWL) within 3 months of postlaparoscopic sleeve gastrectomy (LSG) on clinical outcomes and its correlation with adipocyte function.

Methods: Patients (n = 176) who underwent LSG between January 2019 and January 2023 were included. Weight loss and status of health markers were monitored postoperatively. The cohort was stratified based on EBWL < 37.7% at 3 months or not. Variables including neutrophil-to-lymphocyte ratio (NLR), insulin resistance, and comorbidities were analyzed. Omental visceral and subcutaneous adipose tissue samples were used to analyze the differences in adipocyte function by western blot.

Results: Patients with EBWL < 37.7% at 3 months post-LSG (suboptimal group) comprised less likelihood of achieving ≥ 50% EBWL than those who achieved ≥ 37.7% EBWL (optimal group) at 6 months (42.55% vs. 95.52% in optimal group, p < 0.001), 12 months (85.11% vs. 99.25% in optimal group, p < 0.001) and 24 months (77.14% vs. 94.74% in optimal group, p = 0.009) post-LSG. High BMI (OR = 1.222, 95% CI 1.138-1.312, p < 0.001), NLR ≥ 2.36 (OR = 2.915, 95% CI 1.257-6.670, p = 0.013), and female sex (OR = 3.243, 95% CI 1.306-8.051, p = 0.011) significantly predicted EBWL < 37.7% at 3 months post-LSG. Patients with NLR ≥ 2.36 had significantly lower adipose triglyceride lipase in omental fat (p = 0.025).

Conclusion: EBWL < 37.7% at 3 months post-LSG is a strong predictor of subsequent suboptimal weight loss. High BMI, NLR ≥ 2.36, and female sex are risk factors in predicting EBWL < 37.7% at 3 months post-LSG. These findings may offer a reference to apply adjuvant weight loss medications to patients who are predisposed to suboptimal outcomes.

References
1.
Heymsfield S, Wadden T . Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017; 376(3):254-266. DOI: 10.1056/NEJMra1514009. View

2.
van de Laar A, de Brauw L, Meesters E . Relationships between type 2 diabetes remission after gastric bypass and different weight loss metrics: arguments against excess weight loss in metabolic surgery. Surg Obes Relat Dis. 2015; 12(2):274-82. DOI: 10.1016/j.soard.2015.07.005. View

3.
Obeidat F, Shanti H . Early Weight Loss as a Predictor of 2-Year Weight Loss and Resolution of Comorbidities After Sleeve Gastrectomy. Obes Surg. 2015; 26(6):1173-7. DOI: 10.1007/s11695-015-1903-4. View

4.
Yang P, Chen C, Chen C, Lin M, Wang W . Early weight loss as a predictor of 3-year weight loss and weight regain in patients with good compliance after sleeve gastrectomy. Surg Obes Relat Dis. 2021; 17(8):1418-1423. DOI: 10.1016/j.soard.2021.03.023. View

5.
Su Y, Su Y, Tam K, Yen Y, Wang W, Huang M . Prediction of 5-Year Weight Loss and Weight Regain According to Early Weight Loss after Sleeve Gastrectomy. Obes Surg. 2023; 33(5):1366-1372. DOI: 10.1007/s11695-023-06527-0. View